VISTA: An immune regulatory protein checking tumor and immune cells in cancer immunotherapy

N/ACitations
Citations of this article
146Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized. Here, we review the current knowledge on the therapeutic phenotypes and molecular mechanisms that underlie the contradictory roles of VISTA in checking anti-cancer immune responses. Furthermore, we highlight the potential indeterminacy of VISTA-targeted strategies in cancer immunotherapy, with in silico analyses. In fact, VISTA functions like a homeostatic regulator that actively normalizes immune responses. Thus, the regulatory role of VISTA in anti-cancer immunity remains to be fully elucidated.

Cite

CITATION STYLE

APA

Huang, X., Zhang, X., Li, E., Zhang, G., Wang, X., Tang, T., … Liang, T. (2020, June 29). VISTA: An immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Journal of Hematology and Oncology. BioMed Central. https://doi.org/10.1186/s13045-020-00917-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free